In recent years,the incidence of acute respiratory distress syndrome(ARDS)has been gradually increasing.Despite advances in supportive care,ARDS remains a significant cause of morbidity and mortality in critically ill...In recent years,the incidence of acute respiratory distress syndrome(ARDS)has been gradually increasing.Despite advances in supportive care,ARDS remains a significant cause of morbidity and mortality in critically ill patients.ARDS is characterized by acute hypoxaemic respiratory failure with diffuse pulmonary inflammation and bilateral edema due to excessive alveolocapillary permeability in patients with non-cardiogenic pulmonary diseases.Over the past seven decades,our understanding of the pathology and clinical characteristics of ARDS has evolved significantly,yet it remains an area of active research and discovery.ARDs is highly heterogeneous,including diverse pathological causes,clinical presentations,and treatment responses,presenting a significant challenge for clinicians and researchers.In this review,we comprehensively discuss the latest advancements in ARDS research,focusing on its heterogeneity,pathophysiological mechanisms,and emerging therapeutic approaches,such as cellular therapy,immunotherapy,and targeted therapy.Moreover,we also examine the pathological characteristics of cOvID-19-related ARDS and discuss the corresponding therapeutic approaches.In the face of challenges posed by ARDS heterogeneity,recent advancements offer hope for improved patient outcomes.Further research is essential to translate these findings into effective clinical interventions and personalized treatment approaches for ARDS,ultimately leading to better outcomes for patients suffering from ARDS.展开更多
基金supported by the Technological Innovation 2030-Major Project for the Prevention and Control of Cancer,Cardiovascular and Cerebrovascular Diseases,Respiratory Diseases,and Metabolic Diseases(2024ZD0520200/2024ZD0520204)Development Center for Medical Science&Technology,National Health Commission of the People's Republic of China+5 种基金the National Natural Science Foundation of China(82241060,82272241,82270392,82402574)1.3.5 Project for Disciplinesof Excellence(ZYYC23008ZYGD23035)Center of Excellence-lnternational Cooperation Initiative Grant(139170032)China Postdoctoral Science Foundation(2023M732462)by Projects of Sichuan Provincial Department of Science and Technology(2023ZYD0094).
文摘In recent years,the incidence of acute respiratory distress syndrome(ARDS)has been gradually increasing.Despite advances in supportive care,ARDS remains a significant cause of morbidity and mortality in critically ill patients.ARDS is characterized by acute hypoxaemic respiratory failure with diffuse pulmonary inflammation and bilateral edema due to excessive alveolocapillary permeability in patients with non-cardiogenic pulmonary diseases.Over the past seven decades,our understanding of the pathology and clinical characteristics of ARDS has evolved significantly,yet it remains an area of active research and discovery.ARDs is highly heterogeneous,including diverse pathological causes,clinical presentations,and treatment responses,presenting a significant challenge for clinicians and researchers.In this review,we comprehensively discuss the latest advancements in ARDS research,focusing on its heterogeneity,pathophysiological mechanisms,and emerging therapeutic approaches,such as cellular therapy,immunotherapy,and targeted therapy.Moreover,we also examine the pathological characteristics of cOvID-19-related ARDS and discuss the corresponding therapeutic approaches.In the face of challenges posed by ARDS heterogeneity,recent advancements offer hope for improved patient outcomes.Further research is essential to translate these findings into effective clinical interventions and personalized treatment approaches for ARDS,ultimately leading to better outcomes for patients suffering from ARDS.
